In latest months, Wall Avenue has seen a surge of healthcare companies looking for to go public, as IPO exercise continues to regain momentum after final 12 months’s file lows. MapLight Therapeutics, Inc. is the most recent healthcare firm to leap on the IPO bandwagon, eying a $704 million valuation.
The Providing
In a latest submitting with the Securities and Trade Fee, the corporate revealed its intention to supply 14.75 million shares in an preliminary public providing. Publish-IPO, the inventory is anticipated to commerce on the Nasdaq inventory change below the image MPLT. Morgan Stanley, Jefferies, Leerink Companions, and Stifel are the underwriters managing the providing.
The estimated IPO worth is $17 per share, which interprets into web proceeds of about $227.3 million after deducting providing bills and different prices. The corporate plans to make use of the proceeds to advance the scientific growth of its present applications, to fund analysis and growth actions for added applications, and for working capital and different common company functions.
Loss Widens
MapLight has not but generated income, because it doesn’t have any product available in the market. Within the six months ended June 30, 2025, the corporate incurred a lack of $52.2 million, in comparison with a loss $37.3 million within the corresponding interval final 12 months. Complete working bills had been $54.2 million within the first half.
MapLight is a clinical-stage biopharmaceutical firm engaged within the discovery of therapies for central nervous system issues. Christopher Kroeger, who co-founded the corporate in 2018, has served as its chief government officer, president, and member of the board of administrators since then.
Medical Applications
At present, MapLight is conducting a phase-II trial evaluating its lead product, ML-007C-MA, for the therapy of acute schizophrenia, and expects topline leads to the second half of 2026. As well as, it’s doing an advanced-stage trial evaluating ML-007C-MA for the therapy of ADP, with topline outcomes anticipated within the second half of 2027.
